Arcus Biosciences Inc (RCUS)
15.56
+0.06
(+0.39%)
USD |
NYSE |
Nov 04, 16:00
15.55
-0.01
(-0.06%)
After-Hours: 20:00
Arcus Biosciences Debt to Equity Ratio: 0.00 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
--
Maximum
Dec 2019
--
Average
--
Median
Dec 2019
Debt to Equity Ratio Benchmarks
| Merck & Co Inc | 0.8671 |
| Intra-Cellular Therapies Inc | 0.00 |
| Syndax Pharmaceuticals Inc | 0.00 |
| Clearside Biomedical Inc | 0.00 |
| Janux Therapeutics Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.186B |
| Total Liabilities (Quarterly) | 551.00M |
| Shareholders Equity (Quarterly) | 635.00M |
| Current Ratio | 5.136 |